Headlines about BioMarin Pharmaceutical (NASDAQ:BMRN) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioMarin Pharmaceutical earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 48.5244326423709 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern’s scoring:
A number of equities research analysts have recently issued reports on BMRN shares. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $115.00 target price on shares of BioMarin Pharmaceutical in a research report on Friday, July 14th. Zacks Investment Research upgraded BioMarin Pharmaceutical from a “hold” rating to a “strong-buy” rating and set a $105.00 price target on the stock in a report on Monday, July 17th. ValuEngine downgraded BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a report on Monday, July 17th. Leerink Swann reiterated a “buy” rating on shares of BioMarin Pharmaceutical in a report on Tuesday, July 18th. Finally, Barclays PLC restated an “equal weight” rating and issued a $100.00 target price (down previously from $105.00) on shares of BioMarin Pharmaceutical in a research note on Saturday, July 22nd. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have issued a buy rating to the company. BioMarin Pharmaceutical has an average rating of “Hold” and a consensus target price of $111.55.
Shares of BioMarin Pharmaceutical (BMRN) traded down $0.37 during midday trading on Friday, hitting $82.03. The stock had a trading volume of 842,100 shares, compared to its average volume of 1,247,912. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.91 and a quick ratio of 3.81. BioMarin Pharmaceutical has a 12 month low of $79.50 and a 12 month high of $100.51.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. The company had revenue of $334.18 million during the quarter, compared to analysts’ expectations of $347.38 million. BioMarin Pharmaceutical had a negative return on equity of 4.60% and a negative net margin of 12.45%. BioMarin Pharmaceutical’s revenue for the quarter was up 19.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.02 EPS. sell-side analysts forecast that BioMarin Pharmaceutical will post -0.66 EPS for the current fiscal year.
In other BioMarin Pharmaceutical news, EVP Jeffrey Robert Ajer sold 3,521 shares of the firm’s stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $95.00, for a total transaction of $334,495.00. Following the completion of the sale, the executive vice president now directly owns 49,299 shares in the company, valued at $4,683,405. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Robert Baffi sold 18,415 shares of the firm’s stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $92.43, for a total transaction of $1,702,098.45. Following the sale, the executive vice president now owns 129,083 shares of the company’s stock, valued at $11,931,141.69. The disclosure for this sale can be found here. Insiders have sold 40,686 shares of company stock valued at $3,736,318 in the last quarter. 1.85% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/11/11/biomarin-pharmaceutical-bmrn-earning-somewhat-positive-news-coverage-report-finds.html.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.